Department of Clinical Pharmacy, University of Tennessee Health Science Center, Memphis, Tennessee, USA.
Nutrition. 2011 Jul-Aug;27(7-8):766-72. doi: 10.1016/j.nut.2010.08.009. Epub 2010 Oct 25.
To evaluate glycemic control for critically ill, hyperglycemic trauma patients with renal failure who received concurrent intensive insulin therapy and continuous enteral nutrition (EN) or parenteral nutrition (PN).
Adult trauma patients with renal failure who were given EN or PN concurrently with continuous graduated intravenous regular human insulin (RHI) infusion for at least 3 d were evaluated. Our conventional RHI algorithm was modified for those with renal failure by allowing greater changes in blood glucose (BG) concentrations before the infusion rate was escalated. BG concentration was determined every 1 to 2 h while receiving the insulin infusion. BG control was evaluated on the day before RHI infusion and for a maximum of 7 d while receiving RHI. Target BG during the RHI infusion was 70 to 149 mg/dL (3.9 to 8.3 mmol/L). Glycemic control and incidence of hypoglycemia for those with renal failure were compared with a historical cohort of critically ill, hyperglycemic trauma patients without renal failure given our conventional RHI algorithm.
Twenty-one patients with renal failure who received the modified RHI algorithm were evaluated and compared with 40 patients without renal failure given our conventional RHI algorithm. Average BG concentration was significantly greater for those with renal failure (133±14 mg/dL or 7.3±0.7 mmol/L) compared with those without renal failure (122±15 mg/dL or 6.8±0.8 mmol/L), respectively (P<0.01). Patients with renal failure showed worsened glycemic variability, with 16.1±3.3 h/d within the target BG range, 6.9±3.2 h/d above the target BG range, and 1.4±1.1 h/d below the target BG range compared with 19.6±4.7 h/d (P<0.001), 3.4±3.0 h/d (P<0.001), and 0.7±0.8 h/d (P<0.01) for those without renal failure, respectively. Moderate hypoglycemia (<60 mg/dL or<3.3 mmol/L) occurred in 76% of patients with renal failure compared with 35% without renal failure (P<0.005). Severe hypoglycemia (BG<40 mg/dL or<2.2 mmol/L) occurred in 29% of patients with renal failure compared with none of those without renal failure (P<0.001).
Despite receiving a modified RHI infusion, critically ill trauma patients with renal failure are at greater risk for developing hypoglycemia and have more glycemic variability than patients without renal failure.
评估并发强化胰岛素治疗和连续肠内营养(EN)或肠外营养(PN)的并发肾衰竭的危重病、高血糖创伤患者的血糖控制情况。
评估了至少接受 3 天连续静脉滴注梯度人胰岛素(RHI)输注的并发 EN 或 PN 的成人肾衰竭创伤患者。我们通过允许在增加输注率之前更大地改变血糖(BG)浓度来修改我们的常规 RHI 算法。在接受胰岛素输注时,每 1 到 2 小时测定一次 BG 浓度。在接受 RHI 期间,对 RHI 输注前一天和最多 7 天的 BG 控制进行评估。RHI 输注期间的目标 BG 为 70 至 149mg/dL(3.9 至 8.3mmol/L)。将肾衰竭患者的血糖控制和低血糖发生率与接受我们常规 RHI 算法的无肾衰竭危重病、高血糖创伤患者的历史队列进行比较。
评估了 21 例接受改良 RHI 算法的肾衰竭患者,并与接受我们常规 RHI 算法的 40 例无肾衰竭患者进行比较。与无肾衰竭患者(122±15mg/dL 或 6.8±0.8mmol/L)相比,肾衰竭患者的平均 BG 浓度显著更高(133±14mg/dL 或 7.3±0.7mmol/L)(P<0.01)。肾衰竭患者的血糖变异性恶化,目标 BG 范围内的时间为 16.1±3.3 小时,目标 BG 范围以上的时间为 6.9±3.2 小时,目标 BG 范围以下的时间为 1.4±1.1 小时,而无肾衰竭患者分别为 19.6±4.7 小时(P<0.001)、3.4±3.0 小时(P<0.001)和 0.7±0.8 小时(P<0.01)。肾衰竭患者中有 76%发生中度低血糖(<60mg/dL 或<3.3mmol/L),而无肾衰竭患者中有 35%(P<0.005)。肾衰竭患者中有 29%发生严重低血糖(BG<40mg/dL 或<2.2mmol/L),而无肾衰竭患者中无一人发生严重低血糖(P<0.001)。
尽管接受了改良的 RHI 输注,但并发肾衰竭的危重病创伤患者发生低血糖的风险更高,血糖变异性也更大,与无肾衰竭患者相比。